<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873730</url>
  </required_header>
  <id_info>
    <org_study_id>0881A3-406</org_study_id>
    <nct_id>NCT00873730</nct_id>
  </id_info>
  <brief_title>Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain</brief_title>
  <acronym>Loadet</acronym>
  <official_title>A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg
      twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis
      (AS) and previous failure to usual practice therapies in Spain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20.</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute change ≥ 10 units on a 0-100 scale (0=no disease activity; 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 40.</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = 40% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 50.</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = 50% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 70.</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = 70% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation measured on a 0-100 scale, where 0=no disease activity, 100=high disease activity) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains and no worsening in the remaining domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Partial Remission.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Partial remission defined as a score of less than 20 units (on a scale of 0-100, where 0=no disease activity, 100=high disease activity) in each of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation. For scale, 100=high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nocturnal Back and Overall Spinal Pain From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Nocturnal back and overall spinal pain assessed by patients using a Visual Analog Scale (VAS) of 0 - 10 (0 = no pain and 10 = most severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician and Patient Global Assessment (PGA) of Pain From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Patient pain assessed by physician and patient using a Visual Analog Scale (VAS) of 0 - 10 (0 = none and 10 = severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Functional Index (BASFI) From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>BASFI is a validated self assessment tool that determines the degree of functional limitation in AS patients. Utilizing a VAS of 0-10 (0=easy, 10=impossible), patients answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>BASDAI is a validated self assessment tool used to determine disease activity in patients with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) patient's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI final mean score was calculated taking all 6 VAS assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Metrology Index (BASMI) From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythrocyte Sedimentation Rate (ESR) From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube and is measured in mm/hour. Normal range is 0-30mm/h. A higher rate is consistent with inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Quality of Life (EuroQoL) Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>EuroQol questionnaire is intended to measure the quality of life by means of questions about mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Answers to every question were grouped in two main categories: with problems (having some problems or absolutely unable) or without problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short-Form Health Survey (SF-36) From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Ocular Inflammatory Disease in Patients With Baseline Symptoms</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (CRP) From Baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>CRP is a marker of inflammation and measured in mg/l. A higher level is consistent with inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Etanercept 50 mg twice a week (BIW) for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept/placebo</intervention_name>
    <description>Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of ankylosing spondylitis, as defined by Modified New York Criteria for
             Ankylosing Spondylitis.

          2. Maintained inflammatory activity for more than 12 weeks defined by:·Axial forms:
             BASDAI higher than or equal to 4 (0-10) and at least one of the following parameters:.
             Global assessment of the disease by the patient higher than or equal to 4 (On a scale
             0-10). Spinal pain higher than or equal to 4 on a visual analogue scale (VAS).
             Increase in erythrocyte sedimentation rate (ESR) and/or CRP above the normality
             parameters established by the laboratory.·Peripheral forms: Arthritis or enthesitis
             higher than or equal to 1 site and at least one of the following:. Global assessment
             of the disease by the patient higher than or equal to 4 (on a scale 0-10). Increase in
             erythrocyte sedimentation rate (ESR) and/or CRP above the normality parameters
             established by the laboratory

          3. Failure to treatment: Failure to at least 2 NSAIDs at maximum recommended dose during
             at least 3 months (or a shorter time in case of intolerance, toxicity or
             contraindication).·In cases of ankylosing spondylitis with peripheral joint
             involvement, salazopyrine should have been used at a dose of 2-3 g per day and/or
             methotrexate (15 mg/week) for 4 months (or a shorter time in case of intolerance,
             toxicity or contraindication). In case of oligoarticular or localized involvement in
             enthesis: lack of response, at the discretion of the investigator, to local
             infiltrations and/or synoviorthesis.

          4. Be between 18-70 years of age

          5. Negative result of a pregnancy test in serum in screening visit and in urine in
             baseline visit, done in all women, except those surgically sterilized and those who
             have at least one year of menopause.

          6. Sexually active women of childbearing potential must use medically acceptable
             contraceptive methods, including oral, injectable or implantable contraceptive
             methods, intrauterine devices or properly used barrier contraception. A woman of
             childbearing potential is defined as one who is biologically capable of becoming
             pregnant. This includes women who are using contraceptives or whose sexual partners
             are either sterile or using contraceptives.

          7. Men who are not surgically sterile should agree to use reliable contraceptive methods
             during the study.

          8. Ability to reconstitute the drug and self-inject it or have a person who can do so.

          9. Capability to understand and voluntarily give written informed consent that is signed
             and dated, before any specific procedure of the protocol is performed.

         10. Ability to store injectable test article at 2º to 8º C.

        Exclusion criteria:

          1. Contraindications for treatment with anti-TNF

          2. Complete ankylosis of spine

          3. Onset of treatment with DMARDs in the 4 weeks prior to baseline (SSZ, MTX and HCQ are
             permitted if the administrated dose has been maintained stable in the 4 weeks prior to
             baseline). Furthermore, patients with a dose of prednisone &gt;10 mg/d or equivalent or
             modified in the 2 weeks prior to the baseline visit, those in whose infiltration has
             been performed with intraarticular corticosteroids has been performed in the 4 weeks
             prior to the screening visit and those who follow treatment with more than one NSAID
             in the 2 weeks prior to the baseline visit are excluded.

          4. Previous treatment with other TNF inhibitors and other biological drugs

          5. Abnormalities in hematology profiles defined by:

               -  leukocytes lower than or equal to 3.5 x 10 exponent 9 /L

               -  hemoglobin lower than or equal to 8.5 g/L or 5.3 mmol/L

               -  hematocrit lower than or equal to 27%

               -  platelets lower than or equal to 125 x 10 exponent 9 /L

               -  serum creatinine higher than or equal to 175 mmol/L

               -  aspartate aminotransferase and alanine aminotransferase higher than or equal to 2
                  times the upper limit of normality

          6. Important concomitant medical conditions, such as:-Class III or IV congestive heart
             failure according to New York Heart Association classification-Uncontrolled arterial
             hypertension (defined as screening systolic blood pressure &gt; 160 mm Hg or screening
             diastolic blood pressure &gt; 100 mm Hg)-Myocardial infarction within 12 months of the
             screening visit or unstable angina-Severe pulmonary disease requiring hospitalization
             or oxygen therapy-Diagnosis of multiple sclerosis or other central nervous system
             demyelinating disease -Presence or history of confirmed blood dyscrasias-Cancer or
             history of cancer (other than resected cutaneous basal cell or squamous cell
             carcinoma)-Serious infection (infection requiring hospitalization and/or intravenous
             antibiotics) within 1 month of administration of test article administration or active
             infection at screening or history of recurrent or chronic infection-Open cutaneous
             ulcers-Patients with known chronic infections as positivity to HIV, hepatitis B
             surface antigen (HBsAg), or hepatitis C virus (HCV) -Active tuberculosis infection
             (local guidelines for appropriate screening and treatment of tuberculosis in the
             setting of anti-TNF therapy must be followed)- Any condition that, in the
             investigator's judgment, might cause this study to be detrimental to the subject

          7. Pregnant or breast-feeding women

          8. Past or current psychiatric illness that would interfere with the subject's ability to
             comply with protocol requirements or give informed consent.

          9. Treatment with any live (attenuated) vaccine within 4 weeks prior to baseline.

         10. History of alcohol or drug abuse that would interfere with the subject's ability to
             comply with protocol requirements.

         11. Treatment with any investigational drug within 3 months of screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <results_first_submitted>June 30, 2009</results_first_submitted>
  <results_first_submitted_qc>June 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2009</results_first_posted>
  <last_update_submitted>April 23, 2010</last_update_submitted>
  <last_update_submitted_qc>April 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>Effect of etanercept in subjects with ankylosing spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited in Spain from December 2006 to February 2008.</recruitment_details>
      <pre_assignment_details>Patients were screened up to 6 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept BIW</title>
          <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Etanercept QW</title>
          <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept BIW</title>
          <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Etanercept QW</title>
          <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.22" spread="10.36"/>
                    <measurement group_id="B2" value="42.63" spread="10.66"/>
                    <measurement group_id="B3" value="41.43" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20.</title>
        <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute change ≥ 10 units on a 0-100 scale (0=no disease activity; 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20.</title>
          <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute change ≥ 10 units on a 0-100 scale (0=no disease activity; 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6031</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 40.</title>
        <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = 40% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 40.</title>
          <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = 40% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9166</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 50.</title>
        <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = 50% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 50.</title>
          <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = 50% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7564</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 70.</title>
        <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = 70% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 70.</title>
          <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) patients. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = 70% improvement (vs. baseline) and an absolute change ≥ 20 units on a 0-100 scale (0=no disease activity, 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3266</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.</title>
        <description>ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation measured on a 0-100 scale, where 0=no disease activity, 100=high disease activity) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains and no worsening in the remaining domain.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.</title>
          <description>ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation measured on a 0-100 scale, where 0=no disease activity, 100=high disease activity) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains and no worsening in the remaining domain.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7481</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Partial Remission.</title>
        <description>Partial remission defined as a score of less than 20 units (on a scale of 0–100, where 0=no disease activity, 100=high disease activity) in each of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation. For scale, 100=high disease activity.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Partial Remission.</title>
          <description>Partial remission defined as a score of less than 20 units (on a scale of 0–100, where 0=no disease activity, 100=high disease activity) in each of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation. For scale, 100=high disease activity.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7721</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nocturnal Back and Overall Spinal Pain From Baseline to Week 12.</title>
        <description>Nocturnal back and overall spinal pain assessed by patients using a Visual Analog Scale (VAS) of 0 – 10 (0 = no pain and 10 = most severe pain).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nocturnal Back and Overall Spinal Pain From Baseline to Week 12.</title>
          <description>Nocturnal back and overall spinal pain assessed by patients using a Visual Analog Scale (VAS) of 0 – 10 (0 = no pain and 10 = most severe pain).</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nocturnal Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.96" spread="3.15"/>
                    <measurement group_id="O2" value="-4.15" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Spinal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="2.99"/>
                    <measurement group_id="O2" value="-3.53" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Nocturnal Back Pain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6660</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Overall Spinal Pain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5364</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physician and Patient Global Assessment (PGA) of Pain From Baseline to Week 12.</title>
        <description>Patient pain assessed by physician and patient using a Visual Analog Scale (VAS) of 0 – 10 (0 = none and 10 = severe).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physician and Patient Global Assessment (PGA) of Pain From Baseline to Week 12.</title>
          <description>Patient pain assessed by physician and patient using a Visual Analog Scale (VAS) of 0 – 10 (0 = none and 10 = severe).</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician Global Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.15" spread="1.77"/>
                    <measurement group_id="O2" value="-4.12" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Global Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="3.13"/>
                    <measurement group_id="O2" value="-4.17" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for the Physician Global Assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9426</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for the Patient Global Assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4969</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bath Ankylosing Spondylitis Functional Index (BASFI) From Baseline to Week 12.</title>
        <description>BASFI is a validated self assessment tool that determines the degree of functional limitation in AS patients. Utilizing a VAS of 0–10 (0=easy, 10=impossible), patients answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bath Ankylosing Spondylitis Functional Index (BASFI) From Baseline to Week 12.</title>
          <description>BASFI is a validated self assessment tool that determines the degree of functional limitation in AS patients. Utilizing a VAS of 0–10 (0=easy, 10=impossible), patients answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.61" spread="2.64"/>
                    <measurement group_id="O2" value="-2.45" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6687</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) From Baseline to Week 12.</title>
        <description>BASDAI is a validated self assessment tool used to determine disease activity in patients with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0–10 (0=none and 10=very severe) patient’s answered 6 questions measuring discomfort, pain and fatigue. The BASDAI final mean score was calculated taking all 6 VAS assessments.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) From Baseline to Week 12.</title>
          <description>BASDAI is a validated self assessment tool used to determine disease activity in patients with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0–10 (0=none and 10=very severe) patient’s answered 6 questions measuring discomfort, pain and fatigue. The BASDAI final mean score was calculated taking all 6 VAS assessments.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="2.18"/>
                    <measurement group_id="O2" value="-3.59" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6739</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bath Ankylosing Spondylitis Metrology Index (BASMI) From Baseline to Week 12.</title>
        <description>BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober’s test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bath Ankylosing Spondylitis Metrology Index (BASMI) From Baseline to Week 12.</title>
          <description>BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober’s test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.98"/>
                    <measurement group_id="O2" value="-0.80" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2772</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Erythrocyte Sedimentation Rate (ESR) From Baseline to Week 12.</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube and is measured in mm/hour. Normal range is 0-30mm/h. A higher rate is consistent with inflammation.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erythrocyte Sedimentation Rate (ESR) From Baseline to Week 12.</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube and is measured in mm/hour. Normal range is 0-30mm/h. A higher rate is consistent with inflammation.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="14.47"/>
                    <measurement group_id="O2" value="-16.2" spread="16.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1560</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ankylosing Spondylitis Quality of Life (EuroQoL) Questionnaire</title>
        <description>EuroQol questionnaire is intended to measure the quality of life by means of questions about mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Answers to every question were grouped in two main categories: with problems (having some problems or absolutely unable) or without problems.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population was the intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ankylosing Spondylitis Quality of Life (EuroQoL) Questionnaire</title>
          <description>EuroQol questionnaire is intended to measure the quality of life by means of questions about mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Answers to every question were grouped in two main categories: with problems (having some problems or absolutely unable) or without problems.</description>
          <population>The analysis population was the intent to treat population.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility Without Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility With Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care Without Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care With Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities Without Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities With Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort Without Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort With Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Depression Without Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Depression With Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Mobility.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2099</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Self-care.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8009</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Usual activities.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4290</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Pain/Discomfort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0461</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Anxiety/Depression.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5620</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 36-Item Short-Form Health Survey (SF-36) From Baseline to Week 12.</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population was the intent to treat population. Two scored areas had a different “Number of Participants Analyzed” in the etanercept arm. Bodily pain had 45 and Emotional role limitations had 46.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 36-Item Short-Form Health Survey (SF-36) From Baseline to Week 12.</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
          <population>The analysis population was the intent to treat population. Two scored areas had a different “Number of Participants Analyzed” in the etanercept arm. Bodily pain had 45 and Emotional role limitations had 46.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.53" spread="27.73"/>
                    <measurement group_id="O2" value="19.90" spread="20.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical role limitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.32" spread="50.79"/>
                    <measurement group_id="O2" value="32.14" spread="42.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="22.31"/>
                    <measurement group_id="O2" value="-1.43" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="13.22"/>
                    <measurement group_id="O2" value="9.59" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="13.61"/>
                    <measurement group_id="O2" value="12.14" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.24" spread="16.75"/>
                    <measurement group_id="O2" value="6.12" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional role limitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.39" spread="42.01"/>
                    <measurement group_id="O2" value="17.01" spread="40.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" spread="11.53"/>
                    <measurement group_id="O2" value="6.27" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Physical functioning.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3476</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Physical role limitations.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9045</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Bodily pain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8558</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for General health.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3123</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Vitality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3327</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Social functioning.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8334</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Emotional role limitations.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7998</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis provided for Mental health.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7125</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Ocular Inflammatory Disease in Patients With Baseline Symptoms</title>
        <time_frame>12 weeks</time_frame>
        <population>The population for this assessment was patients who had ocular inflammatory disease at baseline. The number of patients analyzed is zero because no patients had symptoms of ocular inflammatory disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Ocular Inflammatory Disease in Patients With Baseline Symptoms</title>
          <population>The population for this assessment was patients who had ocular inflammatory disease at baseline. The number of patients analyzed is zero because no patients had symptoms of ocular inflammatory disease at baseline.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein (CRP) From Baseline to Week 12.</title>
        <description>CRP is a marker of inflammation and measured in mg/l. A higher level is consistent with inflammation.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The analysis population is the intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept BIW</title>
            <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etanercept QW</title>
            <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (CRP) From Baseline to Week 12.</title>
          <description>CRP is a marker of inflammation and measured in mg/l. A higher level is consistent with inflammation.</description>
          <population>The analysis population is the intent to treat.</population>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="18.42"/>
                    <measurement group_id="O2" value="-11.7" spread="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7404</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etanercept BIW</title>
          <description>etanercept 50 mg twice a week (BIW) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Etanercept QW</title>
          <description>etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrheic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22"/>
                <counts group_id="E2" subjects_affected="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

